Real-World Data of Combined Immunochemotherapy in Patients With Nonsquamous Advanced NSCLC. A Single-Center Retrospective Study

INTRODUCTION: On the basis of the landmark trial KEYNOTE-189 (KN-189), pembrolizumab plus chemotherapy has become the standard-of-care first-line treatment for patients with advanced nonsquamous NSCLC without oncogenic driver alterations. KN-189 included a selected patient population and lacks exter...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallrabenstein, Till, Mamot, Maximilian, Daetwyler, Eveline, König, David, Rothschild, Sacha I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164892/
https://www.ncbi.nlm.nih.gov/pubmed/37168879
http://dx.doi.org/10.1016/j.jtocrr.2023.100509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164892/
https://www.ncbi.nlm.nih.gov/pubmed/37168879
http://dx.doi.org/10.1016/j.jtocrr.2023.100509

Ejemplares similares